Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRASS 2
2023-505261-84-00Phase 3Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, ifosfamide, dacarbazine and epirubicin in retroperitoneal leiomyosarcoma (RLMS), retroperitoneal liposarcoma (RLS), pelvic extraperitoneal leiomyosarcoma and 1 more (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease-free survival. Planned start Aug 2023; status: authorised.
02
Drugs
doxorubicinifosfamidedacarbazineepirubicin
03
Conditions
retroperitoneal leiomyosarcoma (RLMS)retroperitoneal liposarcoma (RLS)pelvic extraperitoneal leiomyosarcomapelvic extraperitoneal liposarcoma
Beyond the preview
Go deeper on 2023-505261-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505261-84-00.